Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Hermansky-pudlak syndrome and prolonged activated partial thromboplastin time

Mala Varma, Ilan Shapira

Blood (2025) 146 (Supplement 1): 6598.

https://doi.org/10.1182/blood-2025-6598

Published: 2025

Journal Articles

Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm

Graham Wehmeyer, Ryan Jin, Vesna Najfeld, Megan Metzger, Theodora Anagnostou, Patricia Arboleda Ezcurra, Janice Gabrilove, Marina Kremyanskaya, John Mascarenhas, Christian Salib, Ilan Shapira, Jonah Shulman, Suchitra Sundaram, Douglas Tremblay, Adam Kittai

Blood (2025) 146 (Supplement 1): 5674.

https://doi.org/10.1182/blood-2025-5674

Published: 2025

Journal Articles

Phase II Study of Danazol with Plasma Exchange and Corticosteroids for the Treatment of Thrombotic Thrombocytopenic Purpura

Vamsee Torri, Mark Friedman, Ilan Shapira, Amit A. Patel, Joseph Yoe, Vijay P. Shah, Tahir Mirzoyev, Maria Machuca, Mala Varma

Blood (2023) 142 (Supplement 1): 4007.

https://doi.org/10.1182/blood-2023-178552

Published: 2023

Journal Articles

A 2 Year of Review of HIT Evaluations at an Urban Medical Center with an Aim Towards Quality Improvement and the Development of Practical Testing Strategies

Stephen Zachary Peeke, MD, Ilan Shapira, MD, Ismini Kourouni, MD

Blood (2017) 130 (Supplement 1): 2322.

https://doi.org/10.1182/blood.V130.Suppl_1.2322.2322

Published: 2017

Journal Articles

Safety and Efficacy of Thrombopoietin Receptor Agonists in Patients with Previously Treated Chronic Immune Thrombocytopenia: A Systematic Review and Meta-Analysis

Yuji Yamada, MD, Takeo Fujii, MD, Caroline Cromwell, MD, Ilan Shapira, MD

Blood (2016) 128 (22): 4925.

https://doi.org/10.1182/blood.V128.22.4925.4925

Published: 2016

Journal Articles

Feasibility of Interim PET-Adapted Therapy in HIV-Positive Patients with Advanced Hodgkin Lymphoma (HL): Sub-Analysis of SWOG S0816 Phase 2 Trial

Alexey V Danilov, MD PhD, Hongli Li, PhD, Oliver W. Press, Ilan Shapira, MD, Lode J. Swinnen, MBChB, Ariela Noy, MD, Erin Reid, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD MMSc

Blood (2015) 126 (23): 1498.

https://doi.org/10.1182/blood.V126.23.1498.1498

Published: 2015

Journal Articles

Anti-Rh(D) Utilization Prior To and Following The FDA Mandate For Hemoglobinuria Screening 03/11/10

Mala Varma, MD, Hrvoje Melinscak, MD, Ilan Shapira, MD, Gabriel Sara, MD, Michael L. Grossbard, MD

Blood (2013) 122 (21): 4761.

https://doi.org/10.1182/blood.V122.21.4761.4761

Published: 2013

Journal Articles

Comparison of Lengths of Stay for Inpatients with Immune Thrombocytopenia Treated with Anti-Rh(D), Intravenous Immunoglobulin, and Steroids

Hrvoje Melinscak, MD, Ilan Shapira, MD, Mala Varma, MD

Blood (2012) 120 (21): 4646.

https://doi.org/10.1182/blood.V120.21.4646.4646

Published: 2012

Journal Articles

Combination of Anti-Rh(D) and Danazol in Patients with Immune Thrombocytopenia

Mala Varma, MD, Ilan Shapira, MD, Ibrahim Nakhoul, MD, Jonah Shulman, MD, David Lucido, PhD, Peter Kozuch, MD, Bruce Culliney, MD, Tahir Mirzoyev, Maria Machuca, Michael L. Grossbard, MD

Blood (2012) 120 (21): 3343.

https://doi.org/10.1182/blood.V120.21.3343.3343

Published: 2012

Journal Articles

Distinct Clinical Characteristics of Myelodysplastic Syndrome in Human Immunodeficiency Virus-Infected Patients,

Koichi Takahashi, MD, Mariko Yabe, MD, Ilan Shapira, MD, Mala Verma, MD

Blood (2011) 118 (21): 3821.

https://doi.org/10.1182/blood.V118.21.3821.3821

Published: 2011

Journal Articles

Phase II Study To Determine If Danazol Is an Anti-D Sparing Agent When Used in Combination with Anti-D for the Treatment of Immune Thrombocytopenic Purpura.

Ibrahim N. Nakhoul, MD, Ilan Shapira, MD, May Abdo-Matkiwsky, MD, Peter Kozuch, MD, Etta Frankel, MD, Sree Bhavani Chalasani, MD, Takhir Mirzoyev, Margaret Dietrich, Peter Homel, PhD, Michael L. Grossbard, MD, Mala Varma, MD

Blood (2006) 108 (11): 3983.

https://doi.org/10.1182/blood.V108.11.3983.3983

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Hermansky-pudlak syndrome and prolonged activated partial thromboplastin time

Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm

Phase II Study of Danazol with Plasma Exchange and Corticosteroids for the Treatment of Thrombotic Thrombocytopenic Purpura

A 2 Year of Review of HIT Evaluations at an Urban Medical Center with an Aim Towards Quality Improvement and the Development of Practical Testing Strategies

Safety and Efficacy of Thrombopoietin Receptor Agonists in Patients with Previously Treated Chronic Immune Thrombocytopenia: A Systematic Review and Meta-Analysis

Feasibility of Interim PET-Adapted Therapy in HIV-Positive Patients with Advanced Hodgkin Lymphoma (HL): Sub-Analysis of SWOG S0816 Phase 2 Trial

Anti-Rh(D) Utilization Prior To and Following The FDA Mandate For Hemoglobinuria Screening 03/11/10

Comparison of Lengths of Stay for Inpatients with Immune Thrombocytopenia Treated with Anti-Rh(D), Intravenous Immunoglobulin, and Steroids

Combination of Anti-Rh(D) and Danazol in Patients with Immune Thrombocytopenia

Distinct Clinical Characteristics of Myelodysplastic Syndrome in Human Immunodeficiency Virus-Infected Patients,

Phase II Study To Determine If Danazol Is an Anti-D Sparing Agent When Used in Combination with Anti-D for the Treatment of Immune Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only